NCT03862651 is a Phase 2 clinical trial of Cangrelor in Platelet Aggregation Inhibitors, sponsored by Ospedale Santa Croce-Carle Cuneo.

Who is sponsoring NCT03862651?

NCT03862651 is sponsored by Ospedale Santa Croce-Carle Cuneo.

What drugs are being tested in NCT03862651?

Interventions in NCT03862651: Cangrelor.

What condition does NCT03862651 study?

NCT03862651 studies Platelet Aggregation Inhibitors.

Is NCT03862651 still recruiting?

NCT03862651 is currently status unknown. Last updated 5 March 2019.

Last reviewed 2019-03-05 · How we verify

NCT03862651

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery (MONET BRIDGE)

Status unknown Phase 2 Last updated 5 March 2019

What this trial tests

Phase 2 trial testing Cangrelor in Platelet Aggregation Inhibitors in 140 participants. Status unknown.

Timeline

1 June 2019

Primary endpoint
31 December 2020

1 January 2021

Quick facts

Lead sponsor	Ospedale Santa Croce-Carle Cuneo
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	treatment
Enrollment	140
Start date	1 June 2019
Primary completion	31 December 2020
Estimated completion	1 January 2021

Drugs / interventions tested

Cangrelor (CANGRELOR) — full drug profile →

Conditions studied

Platelet Aggregation Inhibitors — all drugs for Platelet Aggregation Inhibitors →

Sponsor

Ospedale Santa Croce-Carle Cuneo — full company profile →

Who can join

18 and older, any sex, with Platelet Aggregation Inhibitors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The MONET BRIDGE study is designed to assess the use of cangrelor as a platelet-inhibiting bridge for patients who discontinue DAPT before cardiac and non cardiac surgery within 12 months from coronary stent implantation. It seeks to determine if initiation of a prolonged cangrelor infusion maintains effective platelet inhibition after discontinuation of P2Y12 and whether a cangrelor infusion before cardiac and non cardiac procedures is safe.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives.
De Luca L, Steg PG, Bhatt DL, Capodanno D, et al · · 2021 · cited 62× · PMID 34212768 · DOI 10.1161/jaha.121.022125
Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use.
Capodanno D, Milluzzo RP, Angiolillo DJ. · · 2019 · cited 49× · PMID 31823688 · DOI 10.1177/1753944719893274
Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience.
Rossini R, Masiero G, Fruttero C, Passamonti E, et al · · 2020 · cited 19× · PMID 33376943 · DOI 10.1055/s-0040-1721504

Verify or expand the search:

Other trials of Cangrelor

Trials testing the same drug.

NCT06792643 — Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest rece · Phase 2 · recruiting
NCT05505591 — Intravenous CAngrelor in High-bleeding Risk Patients Undergoing percutaneouS Coronary Intervention (ICARUS) Registry · unknown
NCT04667078 — REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke pat · Phase 3 · recruiting
NCT04790032 — Pharmacodynamic Effects of Cangrelor in ACS or CCS Patients Undergoing PCI (POMPEII Registry) · completed
NCT04668144 — Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI · Phase 4 · completed

Other recruiting trials for Platelet Aggregation Inhibitors

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT05702463 — Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II · Phase 1 · recruiting
NCT03462498 — ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS · Phase 4 · active not recruiting

Other Ospedale Santa Croce-Carle Cuneo trials

Trials by the same sponsor.

NCT05324150 — M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD · completed
NCT04037787 — ERAS (Enhanced Recovery After Surgery) Protocol Implementation in Piedmont Region for Colorectal Cancer Surgery · NA · completed
NCT03368612 — Comparative Study Between the AirGoTM System and Standard Tests in the Assessment of the Respiratory Function · unknown
NCT03645018 — Lung Cancer Early Diagnosis With Digital Tomosynthesis: Re-evaluation of Lung Nodule Detection Rate at 5 Years · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03862651 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ospedale Santa Croce-Carle Cuneo
Last refreshed: 5 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03862651.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing